Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer

被引:12
|
作者
Schoenherr, Regine M. [1 ]
Kelly-Spratt, Karen S. [1 ]
Lin, ChenWei [1 ]
Whiteaker, Jeffrey R. [1 ]
Liu, Tao [2 ]
Holzman, Ted [1 ]
Coleman, Ilsa [1 ]
Feng, Li-Chia [1 ]
Lorentzen, Travis D. [1 ]
Krasnoselsky, Alexei L. [1 ]
Wang, Pei [1 ]
Liu, Yan [1 ]
Gurley, Kay E. [1 ]
Amon, Lynn M. [1 ]
Schepmoes, Athena A. [2 ]
Moore, Ronald J. [2 ]
Camp, David G., II [2 ]
Chodosh, Lewis A. [3 ]
Smith, Richard D. [2 ]
Nelson, Peter S. [1 ]
McIntosh, Martin W. [1 ]
Kemp, Christopher J. [1 ]
Paulovich, Amanda G. [1 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA
[2] Pacific NW Natl Lab, Div Biol Sci, Richland, WA 99352 USA
[3] Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA
关键词
Breast cancer; Her2; Mouse; Proteome; Transcriptome; TANDEM MASS-SPECTROMETRY; CYSTEINYL-PEPTIDE ENRICHMENT; LC-MS; STATISTICAL-MODEL; PERFORMANCE; THROUGHPUT; STANDARDS; PROTEINS; SYSTEM; IDENTIFICATIONS;
D O I
10.1002/prca.201000037
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Purpose: We generated extensive transcriptional and proteomic profiles from a Her2-driven mouse model of breast cancer that closely recapitulates human breast cancer. This report makes these data publicly available in raw and processed forms, as a resource to the community. Importantly, we previously made biospecimens from this same mouse model freely available through a sample repository, so researchers can obtain samples to test biological hypotheses without the need of breeding animals and collecting biospecimens. Experimental design: Twelve datasets are available, encompassing 841 LC-MS/MS experiments (plasma and tissues) and 255 microarray analyses of multiple tissues (thymus, spleen, liver, blood cells, and breast). Cases and controls were rigorously paired to avoid bias. Results: In total, 18 880 unique peptides were identified (PeptideProphet peptide error rate <= 1%), with 3884 and 1659 non-redundant protein groups identified in plasma and tissue datasets, respectively. Sixty-one of these protein groups overlapped between cancer plasma and cancer tissue. Conclusions and clinical relevance: These data are of use for advancing our understanding of cancer biology, for software and quality control tool development, investigations of analytical variation in MS/MS data, and selection of proteotypic peptides for multiple reaction monitoring-MS. The availability of these datasets will contribute positively to clinical proteomics.
引用
收藏
页码:179 / 188
页数:10
相关论文
共 50 条
  • [41] Apigenin Inhibits Growth of Breast Cancer Cells: The Role of ERα and HER2/neu
    Scherbakov, A. M.
    Andreeva, O. E.
    ACTA NATURAE, 2015, 7 (03): : 133 - 139
  • [42] Investigating the Combination of Trastuzumab and HER2/neu Peptide Vaccines for the Treatment of Breast Cancer
    Elizabeth A. Mittendorf
    Catherine E. Storrer
    Craig D. Shriver
    Sathibalan Ponniah
    George E. Peoples
    Annals of Surgical Oncology, 2006, 13 : 1085 - 1098
  • [43] Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer
    Mittendorf, Elizabeth A.
    Storrer, Catherine E.
    Shriver, Craig D.
    Ponniah, Sathibalan
    Peoples, George E.
    ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (08) : 1085 - 1098
  • [44] HER2/neu role in breast cancer: from a prognostic foe to a predictive friend
    Ferretti, Gianluigi
    Felici, Alessandra
    Papaldo, Paola
    Fabi, Alessandra
    Cognetti, Francesco
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2007, 19 (01) : 56 - 62
  • [45] Automated Segmentation and Measurement for Cancer Classification of HER2/neu Status in Breast Carcinomas
    Cheong, Lee Sing
    Jean, Angela
    Tan, Tsu Soo
    Kong, Waiming
    Tan, Soo Yong
    BIOTECHNO 2011: THE THIRD INTERNATIONAL CONFERENCE ON BIOINFORMATICS, BIOCOMPUTATIONAL SYSTEMS AND BIOTECHNOLOGIES, 2011, : 43 - 48
  • [46] HER2 in Breast Cancer: A Review and Update
    Krishnamurti, Uma
    Silverman, Jan F.
    ADVANCES IN ANATOMIC PATHOLOGY, 2014, 21 (02) : 100 - 107
  • [47] Targeting HER2 heterogeneity in breast cancer
    Hamilton, Erika
    Shastry, Mythili
    Shiller, S. Michelle
    Ren, Rongqin
    CANCER TREATMENT REVIEWS, 2021, 100
  • [48] Her2 positive breast cancer: practices
    Campone, Mario
    Berton-Rigaud, Dominique
    Bourbouloux, Emmanuelle
    Sophie, Sadot
    Zanetti, Alain
    Frenel, Jean-Sebastien
    BULLETIN DU CANCER, 2011, 98 (02) : 154 - 163
  • [49] HER2/neu antisense targeting of human breast carcinoma
    Roh, H
    Pippin, JA
    Green, DW
    Boswell, CB
    Hirose, CT
    Mokadam, N
    Drebin, JA
    ONCOGENE, 2000, 19 (53) : 6138 - 6143
  • [50] A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu
    V. Pullarkat
    Y. Deo
    J. Link
    L. Spears
    V. Marty
    R. Curnow
    S. Groshen
    C. Gee
    J. S. Weber
    Cancer Immunology, Immunotherapy, 1999, 48 : 9 - 21